波兰多发性硬化症流行病学的选定的方面:一个多中心试点研究
Joanna Tarasiuk1, Katarzyna Kapica-Topczewska2, Agata Czarnowska2
1Department of Neurology, Medical University of Bialystok, Bialystok, Poland. joanna.tarasiuk@umb.edu.pl.
Neurologia i neurochirurgia polska
|November 20, 2025
概括
波兰多发性硬化症 (MS) 管理已显著改善,广泛使用MRI/CSF,并增加对疾病修饰疗法 (DMT) 的获取,从而改善患者的治疗结果和减少残疾进展.
科学领域:
- 神经学 神经学
- 流行病学 流行病学
- 临床研究 临床研究
背景情况:
- 多发性硬化症 (MS) 是一种进展性神经系统疾病.
- 有效的疾病修饰疗法 (DMT) 越来越多.
- 了解波兰当前的流行病学和临床方面至关重要.
研究的目的:
- 评估波兰MS患者的流行病学和临床特征.
- 将当前数据与15年前的数据进行比较.
- 评估最近治疗进步的影响.
主要方法:
- 这是一项涉及19个波兰治疗中心3,165名多发性硬化症患者的横截面研究.
- 在2024年2月至4月期间,通过标准化问卷收集的数据.
- 包括社会人口统计,临床,诊断和治疗数据.
主要成果:
- 高度使用DMT (97.09%) 具有多种治疗选择.
- 大多数患者 (78.35%) 患有轻度残疾 (EDSS 0-3.5).
- 复发性复发性多发性硬化症 (RRMS) 是主要的亚型 (86.87%).
- 像MRI (99.84%) 和CSF分析 (90.91%) 等先进的诊断方法被广泛使用.
结论:
- 15年来,波兰在多发性硬化症诊断和治疗方面取得了重大进展.
- 更好地获得DMT和诊断工具与更好的临床结果相关.
- 有证据表明复发率降低,残疾进展缓慢,SPMS患病率降低.
相关概念视频
Bioavailability Study Design: Healthy Subjects Versus Patients
136
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
136
Bioavailability Study Design: Single Versus Multiple Dose Studies
189
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
189


